Universitätsklinikum Bonn, Klinik und Poliklinik für Urologie und Kinderurologie, Bonn, Germany
Universitätsklinikum Bonn, Klinik und Poliklinik für Urologie und Kinderurologie, Bonn, Germany.
In Vivo. 2019 Nov-Dec;33(6):1935-1940. doi: 10.21873/invivo.11688.
BACKGROUND/AIM: FGF-2, HGF, MIF and PTN have been suggested as biomarkers for testicular germ cell cancer patients in earlier studies. Our study was designed to validate these potential novel tumor markers.
Serum FGF-2, HGF, MIF and PTN levels were analysed using an ELISA technique in a screening cohort of 20 testicular germ cell cancer patients and 10 healthy men. MIF levels were measured in a validation cohort of 84 patients with testicular cancer, 24 with non-malignant testicular tumors and 64 healthy men.
Serum FGF-2, HGF and PTN levels did not differ in cancer patients and healthy males within the screening cohort, whereas MIF was significantly increased among cancer patients. Within the validation cohort, a modest but insignificant increase of serum MIF was observed in TGCT patients compared to healthy men. MIF levels were not correlated with adverse clinical-pathological parameters.
FGF-2, HGF, MIF and PTN are not suitable as non-invasive biomarkers for testicular germ cell cancer patients.
背景/目的：在之前的研究中，FGF-2、HGF、MIF 和 PTN 被认为是睾丸生殖细胞癌患者的生物标志物。本研究旨在验证这些潜在的新型肿瘤标志物。
使用 ELISA 技术分析了 20 例睾丸生殖细胞癌患者和 10 例健康男性的血清 FGF-2、HGF、MIF 和 PTN 水平。在 84 例睾丸癌患者、24 例非恶性睾丸肿瘤患者和 64 例健康男性的验证队列中测量了 MIF 水平。
在筛选队列中，癌症患者和健康男性的血清 FGF-2、HGF 和 PTN 水平没有差异，而 MIF 在癌症患者中显著升高。在验证队列中，与健康男性相比，TGCT 患者的血清 MIF 略有但无统计学意义的升高。MIF 水平与不良临床病理参数无关。
FGF-2、HGF、MIF 和 PTN 不适合作为睾丸生殖细胞癌患者的非侵入性生物标志物。
